Femasys Inc. is an innovative medical technology company dedicated to transforming women's healthcare through its proprietary solutions for diagnosing and treating gynecological conditions. With a focus on non-surgical alternatives, Femasys is addressing prevalent issues such as uterine fibroids and contraception, positioning itself as a key player in the growing field of women’s health. As demand for minimally invasive treatments continues to rise, the company is strategically equipped to enhance patient outcomes and efficiency in healthcare delivery. By concentrating on significant unmet needs, Femasys aims to set new standards for care in this essential sector.
| Revenue (TTM) | $2.29M |
| Gross Profit (TTM) | $1.42M |
| EBITDA | $-17.25M |
| Operating Margin | -568.00% |
| Return on Equity | -455.80% |
| Return on Assets | -66.30% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $0.10 |
| Price-to-Book | 3.54 |
| Price-to-Sales (TTM) | 11.53 |
| EV/Revenue | 10.57 |
| EV/EBITDA | 0.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 39.90% |
| Shares Outstanding | $60.39M |
| Float | $49.93M |
| % Insiders | 9.28% |
| % Institutions | 10.23% |
Volatility is currently expanding